Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Kilic Eren, Mehtap ^a   Boylu, Tulin ^a   Tabor, Vedrana ^b  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Ewing's sarcoma; HIF 1 ; Hypoxia; PI3K Akt; Rhabdomyosarcoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; DNA BINDING; EWING SARCOMA; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84876081696     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-36     Document Type: Article

References (43)

1. Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2010, 2(3):336-361. 10.1002/wsbm.69, 20836033.
2. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007, 26(14):2027-2038. 10.1038/sj.onc.1210008, 17043658.
3. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998, 8(5):588-594. 10.1016/S0959-437X(98)80016-6, 9794818.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732. 10.1038/nrc1187, 13130303.
5. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9(8):550-562. 10.1038/nrc2664, 19629070.
6. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Crit Rev Oncog 2012, 17(1):69-95. 10.1615/CritRevOncog.v17.i1.60, 22471665.
7. Chen Y, Wang BC, Xiao Y. PI3K: A potential therapeutic target for cancer. J Cell Physiol 2012, 227(7):2818-2821. 10.1002/jcp.23038, 21938729.
8. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009, 9(6):729-737. 10.2174/156800909789271521, 19754357.
9. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000, 60(6):1541-1545.
10. Shafee N, Kaluz S, Ru N, Stanbridge EJ. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett 2009, 282(1):109-115. 10.1016/j.canlet.2009.03.004, 2706285, 19342157.
11. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, Michiels C. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 2003, 278(33):31277-31285. 10.1074/jbc.M300763200, 12764143.
12. O'Brien D, Jacob AG, Qualman SJ, Chandler DS. Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol 2012, 27(1):13-22.
13. Karosas AO. Ewing's sarcoma. Am J Health Syst Pharm 2010, 67(19):1599-1605. 10.2146/ajhp090526, 20852160.
14. Scotlandi K. Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 2006, 587:13-22. 10.1007/978-1-4020-5133-3_2, 17163152.
15. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010, 36(4):318-327. 10.1016/j.ctrv.2010.02.007, 20223596.
16. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007, 67(2):735-745. 10.1158/0008-5472.CAN-06-2201, 17234785.
17. Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 2007, 97(6):785-791. 10.1038/sj.bjc.6603952, 2360380, 17848913.
18. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman S, Tsokos M. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007, 67(7):3431-3440. 10.1158/0008-5472.CAN-06-1344, 17409454.
19. Ahmed AA, Sherman AK, Pawel BR. Expression of therapeutic targets in Ewing sarcoma family tumors. Hum Pathol 2012, 43(7):1077-1083. 10.1016/j.humpath.2011.09.001, 22196127.
20. Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, Fulda S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res 2011, 17(10):3233-3247. 10.1158/1078-0432.CCR-10-2530, 21355080.
21. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, Gorlach A. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007, 18(12):4691-4697. 10.1091/mbc.E07-04-0391, 2096613, 17898080.
22. Ardyanto TD, Osaki M, Tokuyasu N, Nagahama Y, Ito H. CoCl2-induced HIF-1alpha expression correlates with proliferation and apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. Int J Oncol 2006, 29(3):549-555.
23. Dekanty A, Lavista-Llanos S, Irisarri M, Oldham S, Wappner P. The insulin-PI3K/TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-alpha/Sima. J Cell Sci 2005, 118(Pt 23):5431-5441.
24. Zhou J, Schmid T, Frank R, Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 2004, 279(14):13506-13513. 10.1074/jbc.M310164200, 14726529.
25. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001, 12(7):363-369.
26. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008, 68(15):6271-6280. 10.1158/0008-5472.CAN-07-6769, 18676851.
27. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008, 118(11):3660-3670. 10.1172/JCI36157, 2567838, 18924608.
28. Burrows N, Babur M, Resch J, Ridsdale S, Mejin M, Rowling EJ, Brabant G, Williams KJ. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways. J Clin Endocrinol Metab 2011, 96(12):E1934-E1943. 10.1210/jc.2011-1426, 21994956.
29. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7(1):11-20. 10.1016/j.cmet.2007.10.002, 18177721.
30. Jiao M, Nan KJ. Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 2012, 40(2):461-468.
31. Argyriou P, Papageorgiou SG, Panteleon V, Psyrri A, Bakou V, Pappa V, Spathis A, Economopoulou P, Papageorgiou E, Economopoulos T. Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1 > HIF-1alpha pathway. Ann Hematol 2011, 90(3):315-322. 10.1007/s00277-010-1070-6, 20838824.
32. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, Tan M. Emerging metabolic targets in cancer therapy. Front Biosci 2011, 16:1844-1860. 10.2741/3826, 3117434, 21196269.
33. Bian CX, Shi Z, Meng Q, Jiang Y, Liu LZ, Jiang BH. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun 2010, 398(3):395-399. 10.1016/j.bbrc.2010.06.080, 2928061, 20599538.
34. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007, 19(12):2487-2497. 10.1016/j.cellsig.2007.07.025, 2094004, 17826033.
35. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 2000, 28(12):1735-1744. 10.1016/S0891-5849(00)00231-8, 10946215.
36. Liu L, Ning X, Han S, Zhang H, Sun L, Shi Y, Sun S, Guo C, Yin F, Qiao T. [Hypoxia induced HIF-1 accumulation and VEGF expression in gastric epithelial mucosa cell: involvement of ERK1/2 and PI3K/Akt]. Mol Biol (Mosk) 2008, 42(3):459-469.
37. Li L, Qu Y, Mao M, Xiong Y, Mu D. The involvement of phosphoinositid 3-kinase/Akt pathway in the activation of hypoxia-inducible factor-1alpha in the developing rat brain after hypoxia-ischemia. Brain Res 2008, 1197:152-158.
38. Li L, Qu Y, Mao M, Mu D. [Phosphoinositide 3-kinase/Akt pathway involved in regulation of hypoxia inducible factor 1alpha in hypoxia ischemia brain damage of neonatal rats]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2008, 22(9):1102-1107.
39. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 2002, 277(17):15162-15170. 10.1074/jbc.M111162200, 11859074.
40. Alvarez-Tejado M, Alfranca A, Aragones J, Vara A, Landazuri MO, del Peso L. Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 2002, 277(16):13508-13517. 10.1074/jbc.M200017200, 11815624.
41. Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E. [PI3K-AKT-mTOR pathway and cancer]. Bull Cancer 2012, 99(2):173-180.
42. Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, Fulda S. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 2011, 30(4):494-503. 10.1038/onc.2010.429, 20856197.
43. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000, 275(28):21048-21054. 10.1074/jbc.M000636200, 10777486.